GlaxoSmithKline plc S-8


 


Exhibit 4.3


 


AMENDMENT
NO. 1 


TO
THE 


GSK
401(k) PLAN 


(effective
January 1, 2017)


 





 






 


Pursuant
to resolutions of the Board of Managers of GlaxoSmithKline LLC, adopted December 15, 2017, the GSK 401(k) Plan (the “Plan”)
is amended as follows, effective as of January 1, 2017, except as otherwise provided herein:


 


1.            The
definition of “Roth Contribution Account” under the definition of “Account” in Article I of the Plan is
hereby amended in its entirety to read as follows:


 


“‘Roth
Contribution Account’ – the Account to which are credited a Participant’s Roth Contributions, adjusted for income,
gains and losses thereon.”


 


2.             Effective
as of the applicable dates of transfer referenced below, the definition of “Prior Company Matching Contribution” in
Article I of the Plan is hereby amended by adding new subsections (l), (m) and (n) each reading as follows:


 


“(l)         Effective
on the date of the transfer of plan assets into the Plan, for purposes of Section 6.4, amounts denominated under the Novamin Technology,
Inc. Retirement Plan and Trust as “matching contributions” and “non-elective contributions,” “profit
sharing contributions”, “discretionary contributions,” or any other employer contributions, plus any earnings
or minus any losses thereon;


 


(m)         Effective
on the date of the transfer of plan assets into the Plan, for purposes of Section 6.4, amounts denominated under the Tempero 401K
Plan as “matching contributions” and “non-elective contributions,” “profit sharing contributions”,
“discretionary contributions,” or any other employer contributions, plus any earnings or minus any losses thereon;
and


 


(n)          Effective
on the date of the transfer of plan assets into the Plan, for purposes of Section 6.4, amounts denominated under the Human Genome
Sciences, Inc. 401(k) Plan as “matching contributions” and “non-elective contributions,” “profit
sharing contributions”, “discretionary contributions,” or any other employer contributions, plus any earnings
or minus any losses thereon.”


 


3.            The
definition of “Roth Contributions” in Article I of the Plan is hereby amended in its entirety to read as follows:


 


“‘Roth
Contributions’ means, for any Participant, designated contributions described in section 402A(c)(1) of the Code made
on or after October 1, 2009 pursuant to Section 3.1.1.2 by the Company at the Participant’s election; provided that
Roth Contributions shall also include amounts denominated as Roth contributions as described in section 402A(c)(1) of the
Code under a plan merged into the Plan or a plan of which its assets or portion of its assets are transferred to the
Plan.”


 






     


     


    

 


4.            Effective
March 5, 2013, Section 6.1.3 of the Plan is hereby amended by in its entirety to read as follows:


 


“6.1.3.
The total amount of his Prior Company Matching Contribution Account and that portion of the Puerto Rico Employee Account, if any,
attributable to such Prior Company Matching Contributions; provided, however, that the portion of the Prior Company Matching Contribution
Account attributable to Human Genome Sciences, Inc. 401(k) Plan was not eligible for regular withdrawals pursuant to this Section
6.1 between March 5, 2013 and May 31, 2017.”


 


5.            Schedule
B of the Plan is hereby amended by adding the following to the Acquisition Table:


 


	Acquired
    / Affiliated Company	Eligibility
    Service Effective Date
	NovaMin
    Technology, Inc.	December
    21, 2010
	Human
    Genome Sciences, Inc.	September,
    24, 2012 or December 17, 2012
	Tempero
    Phamaceuticals, Inc.	October
    20, 2014


  


Executed
this ___ day of December, 2017.


 


	 	GLAXOSMITHKLINE LLC
	 	 	 
	 	By: 	 
	 	 	 






 






    - 2 -